Chemist + Druggist is part of Pharma Intelligence UK Limited

This is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.


This copy is for your personal, non-commercial use. Please do not redistribute without permission.

Printed By

UsernamePublicRestriction

Plymouth pharmacists gear up for advanced MUR on diabetes

Practice Pharmacists in Plymouth will be undertaking extra training to help patients manage their diabetes more effectively, in a trial of the first advanced MUR in the area.

Pharmacists in Plymouth will be undertaking extra training to help patients manage their diabetes more effectively, in a trial of the first advanced MUR in Devon.


Devon LPC is launching the advanced diabetes MUR across pharmacies in Plymouth pharmacies working towards healthy living pharmacy (HLP) status. The NHS-funded service will enable pharmacists to offer diabetes advice in addition to the normal MUR consultation.


Devon LPC told C+D it expected at least 15 pharmacies to take part in the 10-week trial from June, the results of which will then be evaluated and presented as part of the national evaluation of HLPs to the Parliamentary All Party Diabetes Group later this year.  


Devon LPC is launching the advanced diabetes MUR for pharmacies in Plymouth working to achieve Healthy Living Pharmacy status

More on MURs

MUR tips for type 1 diabetes

Extend MURs and NMS to reduce medicines waste,       says government steering group

C+D MUR Zone

The £4,000 scheme, funded by Plymouth Public Health, builds on the launch of Devon LPC's diabetes toolkit last September. The scheme comes as research from charity Diabetes UK released last week found that just one in five patients in England and Wales had their condition under control.


"We are doing it to influence [pharmacists] to make sure that patients are better able to manage their diabetes," Devon LPC project pharmacist Mark Stone said.


Mr Stone hoped that pharmacists would be delivering five advanced MURs a week. "If we can get 400 MURs and receive feedback on that, then we will be doing well," he added. 


Pharmacists will be paid a fee of between £5 and £10 for each consultation, in addition to the £28 they receive for a normal MUR.  


Diabetes was a growing problem, Mr Stone said, with the Health and Social Care Information Centre claiming earlier this year that five million people in the UK would be diagnosed with the condition by 2025.


Participating pharmacists will need to do an e-training course developed by the London Health Innovation and Education Cluster (HIEC) and attend clinical training, which will enable them to provide advice on hypoglycaemic episodes, insulin injecting techniques, lifestyle changes and medicines compliance.


Mr Stone said the toolkit was being used by pharmacists across the country and a pharmacist in Egham, Surrey had emailed him to say it had changed the way he approached his MURs.


Mr Stone was keen for more pharmacists to take advantage of it. "If we want to make a difference to patients we have to get it out to each and every pharmacist to use it."


For what condition would an advanced MUR benefit your patients most?

Comment below or email us at [email protected] You can also find C+D on Twitter, LinkedIn and Facebook

Topics

         
Pharmacist Manager
Barnsley
£30 per hour

Apply Now
Latest News & Analysis
See All
UsernamePublicRestriction

Register

CD016122

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel